Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Chromos Molecular Systems has published data demonstrating that a monoclonal antibody directed against VLA-2, the target for its multiple sclerosis drug can suppress the signs of disease in an animal model.
Subscribe to our email newsletter
In addition, the data validates VLA-2 as a potential target for early therapeutic intervention in the treatment of multiple sclerosis (MS).
“Currently, there are no FDA approved therapies for MS patients suffering from a relapse. CHR-1103 represents a promising new approach for the treatment of MS relapse and disease compared to the existing portfolio of chronically administered treatments,” said Alistair Duncan, president and CEO.
CHR-1103 is a humanized monoclonal antibody being developed as a broad-based anti-inflammatory agent, with an initial focus on the treatment of acute relapses associated with MS. Unlike therapeutics designed to delay or antagonize the initial stages of inflammation, CHR-1103 is designed to reduce and prevent the accumulation of inflammatory cells within inflamed tissues.